- |||||||||| anti-MICA/B antibody / BMS
Antibody targeting NKG2D ligands MICA/B to unleash anti-tumor immunity of NK and ILC1 cells (Hall C) - Oct 6, 2022 - Abstract #SITC2022SITC_1320; Conclusions Our data elucidated the functional heterogeneity of type I ILCs in prostate tumor microenvironment in a murine model, which has not been previously characterized. Moreover, we showed that targeting MIC with B10G5 could increase heterogeneity of type I innate lymphoid cells in vivo , which potentially contribute to better overall anti-tumor responses.
|